-
公开(公告)号:US07589128B2
公开(公告)日:2009-09-15
申请号:US11143312
申请日:2005-06-01
申请人: Csaba Szabo , Szabolcs Szoke , Lorant Gyuricza , Claude Singer , Valerie Niddam-Hildesheim , Greta Sterimbaum
发明人: Csaba Szabo , Szabolcs Szoke , Lorant Gyuricza , Claude Singer , Valerie Niddam-Hildesheim , Greta Sterimbaum
IPC分类号: A61K47/00
CPC分类号: C07D215/18 , C07D407/06 , F26B5/041 , F26B11/12
摘要: Provided is a process for preparation of amorphous form of an active pharmaceutical ingredient.
摘要翻译: 提供了制备活性药物成分的无定形形式的方法。
-
公开(公告)号:US20130096304A1
公开(公告)日:2013-04-18
申请号:US13535105
申请日:2012-06-27
申请人: Greta Sterimbaum , Sigalit Levi , Adi Yeori , Tamas Koltai , Valerie Niddam-Hildesheim , Maytal Piran , Shay Asis , Hagit Eisen-Nevo , David Malcolm Crowe
发明人: Greta Sterimbaum , Sigalit Levi , Adi Yeori , Tamas Koltai , Valerie Niddam-Hildesheim , Maytal Piran , Shay Asis , Hagit Eisen-Nevo , David Malcolm Crowe
IPC分类号: C07D401/14
CPC分类号: C07D401/14
摘要: Crystalline forms of Nilotinib HCl are described.
摘要翻译: 描述了盐酸尼洛替尼的结晶形式。
-
公开(公告)号:US07531656B2
公开(公告)日:2009-05-12
申请号:US10641750
申请日:2003-08-14
IPC分类号: C07D211/06 , C07D403/04 , C07D401/04
CPC分类号: C07D215/56 , C07D401/04
摘要: Provided are a method for making (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, in high purity, in a suspension in a dipolar aprotic solvent.
摘要翻译: 提供了制备(±)-1-环丙基-6-氟-1,4-二氢-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸的方法,通常 称为加替沙星,高纯度,在偶极非质子溶剂中的悬浮液中。
-
公开(公告)号:US07423153B2
公开(公告)日:2008-09-09
申请号:US10436736
申请日:2003-05-12
IPC分类号: C07D401/04 , A61K31/47
CPC分类号: C07D215/56
摘要: Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of gatifloxacin, in particular forms omega and T2RP.
摘要翻译: 提供加替沙星命名形式为A,B,C,D,E1,F,G,H,I和J的新型结晶形式及其制备方法。 还提供了制备加替沙星的已知结晶形式的方法,特别是形成ω和T2RP。
-
公开(公告)号:US07411067B2
公开(公告)日:2008-08-12
申请号:US10462945
申请日:2003-06-16
IPC分类号: C07D401/04 , A61K31/47
CPC分类号: C07D215/56 , C07D401/04
摘要: Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, and methods for their preparation.
摘要翻译: 提供加替沙星的两种新型结晶形式,称为O型和V型,其制备方法。
-
公开(公告)号:US20080188658A1
公开(公告)日:2008-08-07
申请号:US12080470
申请日:2008-04-02
IPC分类号: C07D401/02
CPC分类号: C07D215/56 , C07D401/04
摘要: Provided is a method for making (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, in high purity, in a suspension in a dipolar aprotic solvent.
摘要翻译: 提供了制备(±)-1-环丙基-6-氟-1,4-二氢-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸的方法,通常 称为加替沙星,高纯度,在偶极非质子溶剂中的悬浮液中。
-
公开(公告)号:US20050256156A1
公开(公告)日:2005-11-17
申请号:US11112790
申请日:2005-04-21
IPC分类号: A61K31/47 , C07D215/16 , C07D215/18
CPC分类号: C07D215/18
摘要: The present invention provides processes for preparing montelukast.
摘要翻译: 本发明提供孟鲁司特的制备方法。
-
公开(公告)号:US08592442B2
公开(公告)日:2013-11-26
申请号:US13535105
申请日:2012-06-27
申请人: Greta Sterimbaum , Sigalit Levi , Adi Yeori , Tamas Koltai , Valerie Niddam-Hildesheim , Maytal Piran , Shay Asis , Hagit Eisen-Nevo , David Malcolm Crowe
发明人: Greta Sterimbaum , Sigalit Levi , Adi Yeori , Tamas Koltai , Valerie Niddam-Hildesheim , Maytal Piran , Shay Asis , Hagit Eisen-Nevo , David Malcolm Crowe
IPC分类号: A01N43/54 , A61K31/505
CPC分类号: C07D401/14
摘要: Crystalline forms of Nilotinib HCl are described.
摘要翻译: 描述了盐酸尼洛替尼的结晶形式。
-
公开(公告)号:US20070072868A1
公开(公告)日:2007-03-29
申请号:US11605565
申请日:2006-11-28
IPC分类号: A61K31/496 , C07D403/02
CPC分类号: C07D215/56 , C07D401/04
摘要: Provided are a method for making (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, in high purity, in a suspension in a dipolar aprotic solvent.
摘要翻译: 提供了制备(±)-1-环丙基-6-氟-1,4-二氢-8-甲氧基-7-(3-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸的方法,通常 称为加替沙星,高纯度,在偶极非质子溶剂中的悬浮液中。
-
公开(公告)号:US20060252772A1
公开(公告)日:2006-11-09
申请号:US11488812
申请日:2006-07-17
IPC分类号: A61K31/496 , C07D403/02
CPC分类号: C07D215/56
摘要: Provided are novel crystalline forms of gatifloxacin, some of which are DMSO solvates, and methods for making them.
-
-
-
-
-
-
-
-
-